Mitchell Chan
Directeur/Membre du Conseil chez AVALO THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Mitchell Chan
Sociétés | Poste | Début | Fin |
---|---|---|---|
AVALO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2021 | - |
Independent Dir/Board Member | 01/12/2021 | - | |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Directeur/Membre du Conseil | 11/03/2020 | - |
Historique de carrière de Mitchell Chan
Anciens postes connus de Mitchell Chan
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIELA BIO, INC. | Comptroller/Controller/Auditor | 01/06/2019 | 15/03/2021 |
Directeur Financier/CFO | 01/06/2019 | 15/03/2021 | |
ASTRAZENECA PLC | Investor Relations Contact | - | - |
Formation de Mitchell Chan
Rotman School of Management | Masters Business Admin |
University of Toronto | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Canada | 3 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 2 |
Comptroller/Controller/Auditor | 1 |
Director of Finance/CFO | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Commercial Services |
- Bourse
- Insiders
- Mitchell Chan
- Expérience